Cellectis: Funding, Investors & Team (Sep 2026)
Cellectis is a biopharmaceutical company that is pioneering a groundbreaking approach to CAR-T immunotherapies for cancer treatment. They are developing off-the-shelf and ready-to-use gene-edited CAR T-cells, using their expertise in gene editing and innovative technologies like TALEN® and PulseAgile. Their goal is to provide life-saving UCART product candidates for a range of cancers, including AML, B-ALL, MM, HL, and NHL. Headquartered in Paris, France, Cellectis also has locations in New York and North Carolina. They are listed on the Nasdaq Global Market and Euronext Growth. For more information, visit their website or follow them on Twitter and YouTube. (Note: TALEN® is a registered trademark of the Cellectis Group.)
Cellectis has raised $147M across 3 funding rounds on record, the most recent an undisclosed round of $80.0M announced in Nov 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cellectis Company Profile and Key Stats
Latest funding round on record: Nov 2023.
Cellectis Funding Rounds
Cellectis raised $42.6M in an undisclosed round announced in Dec 2022.
2 months later, an undisclosed round of $24.4M was announced in Feb 2023.
9 months later, an undisclosed round of $80.0M was announced in Nov 2023.
Cellectis Founders and Leadership Team
No contact details are on record for this team yet.
Cellectis Funding Compared to Other Biotechnology Startups
Cellectis' latest round of $80.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cellectis in Biotechnology and Paris
Companies Similar to Cellectis
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Cellectis Funding FAQs
What does Cellectis do?
Cellectis is a biopharmaceutical company that is pioneering a groundbreaking approach to CAR-T immunotherapies for cancer treatment. They are developing off-the-shelf and ready-to-use gene-edited CAR T-cells, using their expertise in gene editing and innovative technologies like TALEN® and PulseAgile. Their goal is to provide life-saving UCART product candidates for a range of cancers, including AML, B-ALL, MM, HL, and NHL. Headquartered in Paris, France, Cellectis also has locations in New York and North Carolina. They are listed on the Nasdaq Global Market and Euronext Growth. For more information, visit their website or follow them on Twitter and YouTube. (Note: TALEN® is a registered trademark of the Cellectis Group.)
How much funding has Cellectis raised?
Cellectis has raised $147M across 3 rounds on record. The most recent is an undisclosed round of $80.0M announced in Nov 2023.
When did Cellectis last raise funding?
Cellectis' most recent funding round on record is an undisclosed round of $80.0M, announced in Nov 2023.
Who founded Cellectis?
FundedIQ lists David Sourdive (Founder), Jean Charles Epinat (Founder) at Cellectis.
Where is Cellectis headquartered?
Cellectis is based in Paris, Ile-De-France, France.
How many employees does Cellectis have?
Cellectis is in the 251-500 employee band.
How does Cellectis' funding compare to other Biotechnology startups?
Cellectis' latest round of $80.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Cellectis Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cellectis is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.